# IQVIA's blowout quarter revealed a growing contract backlog, which is the strongest possible signal of future revenue because these orders are locked in and will be billed over the coming years. The broader healthcare sector has been quiet while mega-cap _AI-generated trading idea · BULLISH · IQV_ > Canonical page: https://commonquant.ai/research/for-you/iqvia-s-blowout-quarter-revealed-a-growing-contract-backlog--1ed5d37d-1de7-4f96-84a9-0ec94cc120aa IQVIA's blowout quarter revealed a growing contract backlog, which is the strongest possible signal of future revenue because these orders are locked in and will be billed over the coming years. The broader healthcare sector has been quiet while mega-cap tech and AI stocks grabbed all the attention and pushed the S&P 500 to record highs, leaving companies like IQVIA under-owned by traders chasing flashier stories. When a boring but essential business posts accelerating growth, institutional money tends to rotate in steadily rather than spike all at once, creating an opportunity to ride a multi-week trend rather than chasing a one-day pop. ## Idea IQVIA's blowout quarter revealed a growing contract backlog, which is the strongest possible signal of future revenue because these orders are locked in and will be billed over the coming years. The broader healthcare sector has been quiet while mega-cap tech and AI stocks grabbed all the attention and pushed the S&P 500 to record highs, leaving companies like IQVIA under-owned by traders chasing flashier stories. When a boring but essential business posts accelerating growth, institutional money tends to rotate in steadily rather than spike all at once, creating an opportunity to ride a multi-week trend rather than chasing a one-day pop. ## Advanced Analysis ### Verdict: The IQVIA backlog story is real, but the trade is 15% early The idea's core claim — that IQVIA is a demand-verified, under-owned compounder due for institutional rotation — has genuine support: fiscal 2025 delivered $16.3B of revenue (up 5.9%), $1.36B of net income, $2.05B of free cash flow, and a 99th-percentile free-cash-flow rank among Health Care peers, while the share count fell from 176.1M to 166.9M. But the freshest evidence cuts against the timing. The most recent 13F cycle (June 30, 2026 report period, filing deadline passed) shows net open-market insider selling of roughly $29.2M, net margin compressed to 6.6% from 8.3% sequentially, debt-to-equity rose to 2.25, and the stock closed at $256.05 with the 14-day RSI at 77.09 — 32 points above the setup's own 45 trigger and 15% above the $217.35 50-day EMA entry. The strongest point for the trade is the elite cash generation backing the backlog narrative; the strongest point against is that insiders were net sellers and the entry conditions are nowhere near being met. A verified insider return to net buying, or a September 30 filing that flips the flow, is the fact that would change this verdict. (Scope note: the rule-based setup could not be evaluated because IQVIA daily market-data coverage could not be verified, so this read rests on live levels, fundamentals, and positioning.) #### Conviction score breakdown Composite score computed by the server from the applicable evidence-tier dimensions. | Measure | Value | | --- | ---: | | Thesis support | 55/100 | | Trade readiness | 15/100 | | Risk quality | 40/100 | | Fundamentals trend | 55/100 | | Score | 41/100 | | Composite Score | 41/100 | | Evidence Tier | not\_backtestable | #### Decision scenarios Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts. | Measure | Value | | --- | ---: | | Evidence Tier | not\_backtestable | ### Trade now: no entry — IQVIA is extended above every trigger IQVIA closed at $256.05, and the setup is a \*\*wait\*\*. The strategy wants a pullback long: price below the 50-day EMA (now $217.35), above the lower Bollinger band (the 20-day band sits at $237.12, so this condition is currently met), a 14-day RSI at or below 45, and the RSI having just crossed back above 40. Right now only the band condition is satisfied. Price sits $38.70 above the EMA — a 15.1% pullback needed — and the RSI at 77.09 is more than 32 points above the 45 ceiling. Nothing here is close to triggering today. If an entry did fill, the exits are mechanical: a 2% stop loss versus a 4% take-profit (a 2-to-1 reward-to-risk ratio), with a hard time exit after 40 trading days. Support-based exits use the second-ranked support near $240 and the first-ranked resistance at $251.36 — note that resistance currently sits below the price, a sign of how extended the tape is. One scope note: daily market-data coverage for IQVIA could not be verified within the analysis retry window, so the frozen rule set could not be evaluated and no robust parameter setup was established. That does not change today's action — the live levels above already say wait. Concretely, "wait" means: do not chase; set alerts at $217.35 (price) and 45 (RSI) and re-read this setup only when both are in range. The thesis (a backlog-driven, under-owned healthcare name due for institutional rotation) argues patience will be rewarded, but the numbers argue the trade is late, not early: the stock is at its range high, up 63.4% from the range low, and the 50-day simple average at $211.35 confirms how far price has run above trend. #### IQV price and trigger map Uses the idea timeframe and keeps price levels on the price axis. | Measure | Value | | --- | ---: | | Ticker | IQV | | Timeframe | 1d | ### A Backlog Story That the Numbers Actually Back Up The core of the idea — that IQVIA is a demand-verified business flying under the radar — has real fundamental support. Fiscal 2025 closed with $16.3B of revenue, up 5.9% year over year, net income of $1.36B, and $2.1B of free cash flow. Against a Health Care peer set of roughly 660-990 companies, those results place IQVIA in the 99th percentile for free cash flow, the 87th percentile for operating margin (13.4%), and the 84th percentile for return on equity (20.9%). This is not a turnaround story hoping for demand; the demand is already in the reported numbers, which is consistent with the growing-contract-backlog framing in the cited Yahoo Finance piece on the blowout quarter. The trajectory also fits the thesis. Quarterly revenue has climbed steadily from $3.83B in Q1… #### IQV Debt to equity Debt to equity trend from CommonQuant fundamentals/XBRL data; -87.4% from first to latest point. | Measure | Value | | --- | ---: | | 2012-12-31 | \-1.7403927701112818 ratio | | 2013-03-31 | \-1.7803735455984055 ratio | | 2013-06-30 | \-2.5626483288182063 ratio | | 2013-09-30 | \-2.868151192400771 ratio | | 2013-12-31 | \-3.0498072407939314 ratio | | 2014-03-31 | \-3.6306369911738527 ratio | | 2014-06-30 | \-3.2610606726098825 ratio | | Latest Value | \-3.2610606726098825 ratio | | Change Pct | \-87.37498388949112 ratio | | Ticker | IQV | | Timeframe | reported periods | #### IQV sector percentile check Ranks IQV against 757 companies in its sector using CommonQuant fundamentals. | Measure | Value | | --- | ---: | | Free cash flow | \99.07529722589167th percentile | | Operating margin | \87.16814159292035th percentile | | Return on equity | \83.77281947261663th percentile | | Revenue growth (YoY) | \33.18250377073906th percentile | | Ticker | IQV | | Sector | Health Care | | Peer Count | 757 | ### Scores - **Conviction score breakdown:** 41 - **Thesis support:** 55 - **Trade readiness:** 15 - **Risk quality:** 40 - **Fundamentals trend:** 55 ### Watch items - **IQV — RSI (14)** - **IQV — Close vs 50-day EMA** - **IQV — Close vs lower Bollinger (20)** - **IQV — Insider net open-market activity** - **IQV — Next quarterly earnings report** - **IQV — Debt-to-equity** - **IQV — Price below EMA (50)** - **IQV — Price above Bollinger (20)** - **IQV — RSI (14) below 45** - **IQV — RSI (14) crossed above 40** ## Key details - Symbols: IQV - Timeframes: 1d - Tags: \#canonical-demand, \#cluster-version:1, \#direction:bullish, \#entity-kind:instrument, \#entity:IQV, \#horizon:unspecified, \#intent:research, \#symbol:IQV ## Community - Upvotes: 1 - Views: 0 - Copies: 0 - Cosigns: 0 ## News sources - [The Backlog Tells the Real Story: Inside IQVIA's Blowout Q2](https://finance.yahoo.com/healthcare/articles/backlog-tells-real-story-inside-135910451.html) — Yahoo Finance ## Related - [IQV trade ideas](https://commonquant.ai/stocks/iqv) - [Latest market news](https://commonquant.ai/news) ## About CommonQuant Research Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (12-month and 5-year, walk-forward tuned) and stress-tested before they can go live, then monitored against the news hourly while they run.